.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

EP. 1: Understanding Nonmetastatic CRPC: An Overview

December 28th 2017

EP. 2: Approaching the Treatment of Nonmetastatic CRPC

December 28th 2017

EP. 3: The Value of AR-Targeted Therapy in CRPC

December 28th 2017

EP. 4: Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC

December 28th 2017

EP. 5: Nonmetastatic CRPC: Considerations for Apalutamide

December 28th 2017

EP. 6: MFS: A New Endpoint for Nonmetastatic CRPC

December 28th 2017

EP. 7: Darolutamide's Role in Treating Nonmetastatic CRPC

December 28th 2017

EP. 8: Enzalutamide in the Context of Nonmetastatic CRPC

December 28th 2017

EP. 9: Nonmetastatic CRPC: The Changing Landscape of Treatment

December 28th 2017

EP. 10: The Future of Treatment for Nonmetastatic CRPC

December 28th 2017